BIIB Q4 2018 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.5B+6.6% YoY

Gross Profit

$3.0B86.1% margin

Operating Income

$1.4B40.9% margin

Net Income

$947M26.8% margin

EPS (Diluted)

$4.73

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

$1.9B

Free Cash Flow

$1.7B

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$25.3B

Total Liabilities

$12.3B

Stockholders' Equity

$13.0B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.5B	$3.3B	+6.6%
Gross Profit	$3.0B	$2.8B	+8.6%
Operating Income	$1.4B	$1.5B	-1.6%
Net Income	$947M	-$297M	+418.4%

Revenue Segments

Product

$2.8B80%

Revenues from anti-cd20 therapeutic programs

$535M15%

Product and Service, Other

$166M5%